194 related articles for article (PubMed ID: 19609532)
1. High risk NSGCT: case for surveillance.
Kakiashvili DM; Zuniga A; Jewett MA
World J Urol; 2009 Aug; 27(4):441-7. PubMed ID: 19609532
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
[TBL] [Abstract][Full Text] [Related]
6. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
8. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Sheinfeld J
Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
[TBL] [Abstract][Full Text] [Related]
9. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
11. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy.
Kollmannsberger C; Moore C; Chi KN; Murray N; Daneshmand S; Gleave M; Hayes-Lattin B; Nichols CR
Ann Oncol; 2010 Jun; 21(6):1296-1301. PubMed ID: 19875756
[TBL] [Abstract][Full Text] [Related]
12. National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.
Labbate CV; Werntz RP; Galansky LB; Packiam VT; Eggener SE
Urol Oncol; 2020 Aug; 38(8):687.e13-687.e18. PubMed ID: 32305267
[TBL] [Abstract][Full Text] [Related]
13. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Klein EA
BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
[TBL] [Abstract][Full Text] [Related]
14. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.
Sturgeon JF; Moore MJ; Kakiashvili DM; Duran I; Anson-Cartwright LC; Berthold DR; Warde PR; Gospodarowicz MK; Alison RE; Liu J; Ma C; Pond GR; Jewett MA
Eur Urol; 2011 Apr; 59(4):556-62. PubMed ID: 21190791
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.
Pierorazio PM; Cheaib JG; Patel HD; Gupta M; Sharma R; Zhang A; Tema G; Bass EB
J Urol; 2021 Feb; 205(2):370-382. PubMed ID: 32915080
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy analysis of three therapeutic modes on clinical stage Ia nonseminomatous germ cell testicular tumors].
Dong P; Liu ZW; Li XD; Wu S; Li YH; Yao K; Qin ZK; Han H; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2013 Mar; 51(3):256-60. PubMed ID: 23859330
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of testicular germ cell tumors relapse].
Carbonnaux M; Vinceneux A; Peyrat P; Fléchon A
Bull Cancer; 2020 Sep; 107(9):912-924. PubMed ID: 32653158
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcome in patients with stage-I nonseminomatous germ cell cancer. A critical review of own treatment modalities in a retrospective study.
Seseke S; Bierwirth S; Strauss A; Ringert RH; Seseke F
Int Braz J Urol; 2008; 34(6):715-22; discussion 723-4. PubMed ID: 19111076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
